Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.
Citations
Citations to this article as recorded by
Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity Jae Hyun Bae, Young Min Cho Journal of Diabetes Investigation.2025; 16(2): 183. CrossRef
Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease Kathryn L. Williams, Maya Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka Progress in Pediatric Cardiology.2025; 76: 101775. CrossRef
The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy Chien-Yin Kuo, Sing-Hua Tsou, Edy Kornelius, Kuei-Chuan Chan, Kai-Wei Chang, Jung-Chi Li, Chien-Ning Huang, Chih-Li Lin Cellular and Molecular Life Sciences.2025;[Epub] CrossRef
An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits Laxman Subedi, Arjun Dhwoj Bamjan, Susmita Phuyal, Jung-Hyun Shim, Seung-Sik Cho, Jong Bae Seo, Kwan-Young Chang, Youngro Byun, Seho Kweon, Jin Woo Park Journal of Controlled Release.2025; 378: 637. CrossRef
Engineering a high‐throughput clone for industrial‐scale production of long‐acting GLP‐1 analogue with retained bio‐efficacy Praveen Kumar Reddy J, Murali Tummuru, Kunka Mohanram Ramkumar Biotechnology Progress.2025;[Epub] CrossRef
Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions Iryna Halabitska, Liliia Babinets, Valentyn Oksenych, Oleksandr Kamyshnyi Biomedicines.2024; 12(8): 1630. CrossRef
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies Vincenzo Rochira, Carla Greco, Stefano Boni, Francesco Costantino, Leonardo Dalla Valentina, Eleonora Zanni, Leila Itani, Marwan El Ghoch Diseases.2024; 12(9): 204. CrossRef
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders John O Olukorode, Dolapo A Orimoloye, Nwachukwu O Nwachukwu, Chidera N Onwuzo, Praise O Oloyede, Temiloluwa Fayemi, Oluwatobi S Odunaike, Petra S Ayobami-Ojo, Nwachi Divine, Demilade J Alo, Chukwurah U Alex Cureus.2024;[Epub] CrossRef
Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism Jorge F.A. Model, Rafaella S. Normann, Éverton L. Vogt, Maiza Von Dentz, Marjoriane de Amaral, Rui Xu, Tsvetan Bachvaroff, Poli Mara Spritzer, J. Sook Chung, Anapaula S. Vinagre Biochemical Pharmacology.2024; 230: 116623. CrossRef
Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies Karen Feghali, Xilong Li, Naim M. Maalouf Kidney360.2024; 5(11): 1706. CrossRef
Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway Mingyun Tang, Long Zhao, Fuchun Huang, Tiangang Wang, Xu Wu, Shanshan Chen, Juan Fu, Chaoli Jiang, Shulin Wei, Xuseng Zeng, Xiaoling Zhang, Xin Zhou, Mei Wei, Zhi Li, Guohui Xiao Frontiers in Nutrition.2024;[Epub] CrossRef
Spotlight on the Mechanism of Action of Semaglutide Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi Current Issues in Molecular Biology.2024; 46(12): 14514. CrossRef